Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY turns Leiner corner

This article was originally published in The Tan Sheet

Executive Summary

NBTY's acquisition of Leiner Health Products scared some investors initially, but now they see the integration of the private-label supplement maker as a success, NBTY President and Chief Financial Officer Harvey Kamil says. The stock market appreciates "that we were able to make" Leiner "a profitable acquisition," Kamil said Sept. 23 at the Canaccord Adams Healthy Living Conference. He said NBTY was "squeezed" because it paid "very high prices" for products to build up inventory to serve Leiner's customers. From buying Leiner in June 2008 through March 2009, NBTY took losses on many of the items it shipped, but it made the deal profitable after raising prices in April, Kamil added (1"The Tan Sheet" June 16, 2008). For the April-June period, the firm reported flat net income due to higher costs despite a 21.9 percent increase in net sales to $651.7 million (2"The Tan Sheet" Aug. 17, 2009)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel